NextCure (FRA:2US) Purchase Of Investment : €-49.04 Mil (TTM As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is NextCure Purchase Of Investment?

NextCure's purchase of investment for the three months ended in Mar. 2024 was €-10.25 Mil. It means NextCure spent €10.25 Mil on purchasing investments. NextCure's purchase of investment for the trailing twelve months (TTM) ended in Mar. 2024 was €-49.04 Mil.

Compared with last quarter (€-10.84 Mil in Dec. 2023 ), NextCure spent less money on purchasing investments in Mar. 2024 (€-10.25 Mil).

NextCure Purchase Of Investment Historical Data

The historical data trend for NextCure's Purchase Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NextCure Purchase Of Investment Chart

NextCure Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Purchase Of Investment

Get a 7-Day Free Trial

-270.50

-112.72

-138.48

-32.70

-67.40

NextCure Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Purchase Of Investment	Get a 7-Day Free Trial															-29.33	-27.95	-	-10.84	-10.25

NextCure Purchase Of Investment Calculation

Purchase of Investments represents cash outflow on the purchase of investments in securities.

Purchase Of Investment for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-49.04 Mil.

NextCure Purchase Of Investment Related Terms

Thank you for viewing the detailed overview of NextCure's Purchase Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.

NextCure (FRA:2US) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NextCure Inc (FRA:2US) » Definitions » Purchase Of Investment

Comparable Companies

Traded in Other Exchanges

NXTC:USA

Address

9000 Virginia Manor Road, Suite 200, Beltsville, MD, USA, 20705

Website

https://www.nextcure.com

NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include NC410 a fusion protein of LAIR-2, a naturally occurring soluble version of and decoy protein for LAIR-1 and is designed to block immune suppression mediated by LAIR-1, NC762 a monoclonal antibody that binds specifically to human B7 homolog 4 protein, or B7-H4, a protein expressed on multiple tumor types, and NC525 (LAIR-1 mAb) is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia, or AML, blast cells, and leukemic stem cells, or LSCs.

NextCure (FRA:2US) Headlines

No Headlines